GCKR and hepatocellular carcinoma: In a cohort of 2566 NAFLD patients evaluated for suspected liver disease or who underwent liver biopsy during bariatric surgery, of which 226 with HCC, variants in PNPLA3-TM6SF2-GCKR-MBOAT7 were combined in a hepatic fat PRS (PRSHFC), and then adjusted for HSD17B13 (PRS-5).